Form 4: ALX Oncology Director Acquires Stock Options
SEC Form 4 Filing
Director J. Scott Garland acquired stock options for 20,200 shares of ALX Oncology Holdings Inc on June 13, 2024.
Summary
- On June 13, 2024, J. Scott Garland, a director of ALX Oncology Holdings Inc, acquired stock options for 20,200 shares.
- The exercise price of the stock options is $8.44.
- The options vest in 12 equal monthly installments starting on the 13th day of each month, or earlier if the next annual meeting of stockholders occurs sooner.
- The expiration date for the options is June 12, 2034.
- Following the transaction, Garland directly owns 20,200 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock option acquisition by a company director.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of their confidence in the company's future prospects.
Stakeholder Impact
- The acquisition of stock options by a director may signal confidence in the company's future performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of the transaction where stock options were acquired |
| 06/14/2024 | Date of signature for the Form 4 filing |
| 06/12/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.